Dr. Yen-Ling Chiu, Director of the Department of Medical Research at Far Eastern Memorial Hospital, has led a multidisciplinary and multi-center team to develop an innovative blood test that can identify patients with mild cognitive impairment (MCI) by analyzing the number of T cells in the blood that specifically respond to amyloid proteins. This groundbreaking technique holds promise as a key tool for the early diagnosis of dementia.
Early Detection and Intervention: Overcoming the Challenges of Early Dementia Diagnosis
Mild cognitive impairment (MCI) is considered a precursor to dementia, making early detection and intervention crucial. Current diagnostic methods for cognitive impairment rely heavily on clinical symptoms, neuropsychological tests, and brain imaging, which often only become evident in the later stages of the disease. This delay in detection can result in missed opportunities for early intervention. While current biomarker tests, such as cerebrospinal fluid analysis and PET scans, offer high accuracy, their invasive nature and high cost limit their widespread use.
Five Major Advantages: Precision T-Cell Testing for MCI Detection
Research has shown that T-cell responses to amyloid proteins in the blood can more sensitively reflect changes in brain pathology. This new testing technology focuses on the immune response of T cells to amyloid proteins. The process involves isolating T cells from the blood, stimulating them with specially designed amyloid protein fragments, and then using multiplex biological fluorescence staining and flow cytometry to accurately analyze the immune response of T cells to the amyloid proteins.
The advantages of this technology include:
- Non-Invasiveness: The test only requires a blood sample, eliminating the need for invasive procedures or expensive imaging tests, thereby improving accessibility.
- Cost-Effectiveness: Blood tests are low-cost and do not require specialized high-cost imaging equipment, reducing the overall testing cost and enhancing feasibility and affordability.
- Early Diagnosis: The test can detect abnormalities in the early stages of the disease, offering patients an earlier opportunity for treatment and potentially slowing disease progression.
- High Accuracy: The test boasts an AUROC (Area Under the Receiver Operating Characteristic curve) of over 0.9 for MCI detection, significantly higher than the existing p-Tau181 test (AUROC=0.72).
- Dynamic Monitoring: The test has the potential to track disease progression and assess treatment efficacy through multiple tests, providing a basis for personalized treatment.
Dr. Yen-Ling Chiu emphasized that this testing technology allows patients to receive treatment earlier, thereby slowing the progression of the disease. It also provides healthcare professionals with a more accurate diagnostic tool, aiding in the development of more effective treatment plans. The technology has already been patented in multiple countries, and efforts are underway to explore industry-academic partnerships to accelerate commercialization. In the future, collaboration with diagnostic reagent manufacturers or precision medicine laboratories could lead to the development of more convenient testing products or services.
Resource (mandarin): 早期失智判讀方式注新血！ T細胞檢測辨識認知障礙
